Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

1.026 -0.034 (-3.20%)
Streaming Delayed Price Updated: 11:28 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Updates to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.